Fermenta Biotech Secures FSSAI Approval for Plant‑Source Vitamin D3

What Fermenta Biotech announced

On 6 July 2026, Fermenta Biotech Ltd filed a press release with the Bombay Stock Exchange stating that it has received approval from the Food Safety and Standards Authority of India (FSSAI) for its Vitamin D3 (cholecalciferol) – Plant Source product. The clearance confirms that the product meets all safety, quality and labeling requirements set by the regulator for use as a food supplement in India.

"Fermenta Biotech is pleased to announce that its plant‑derived Vitamin D3 has been granted FSSAI approval, enabling us to bring a sustainable, vegan‑friendly source of cholecalciferol to the Indian market."

Details of the FSSAI approval

The FSSAI approval covers the entire product lifecycle – from raw material sourcing to final packaging. The plant‑source Vitamin D3 is derived from genetically engineered yeast, offering a non‑animal alternative to traditional lanolin‑based Vitamin D3. The regulator’s assessment focused on:

• Safety: Toxicological studies demonstrated no adverse effects at the intended dosage levels.
• Purity: The product complies with the maximum permissible limits for heavy metals, pesticides and microbial contamination.
• Labeling: All mandatory information, including nutrient content, usage instructions and allergen statements, meets FSSAI guidelines.

The filing does not disclose any commercial terms, pricing strategy or projected sales volumes associated with the newly approved product.

Key facts at a glance

Why this matters for investors

The approval removes a key regulatory barrier, allowing Fermenta Biotech to commercialise a plant‑based Vitamin D3 that aligns with growing consumer demand for vegan and sustainable nutraceuticals. Because the filing contains no information on capital raising, share issuance or debt, there is no immediate dilution or cash‑flow impact evident. However, the ability to launch the product could broaden the company’s addressable market and diversify its product portfolio, factors that may be relevant to long‑term valuation assessments.

Conclusion

Fermenta Biotech Ltd’s receipt of FSSAI clearance for its plant‑source Vitamin D3 marks a regulatory milestone that enables the company to proceed with production and sales in India. The filing does not provide financial forecasts or further regulatory steps, leaving the commercial rollout timeline and revenue contribution to be clarified in future disclosures.